Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis
Bone-Tech logo AMSTERDAM, Nov. 17, 2021 (GLOBE NEWSWIRE) — Emultech and Osteo-Pharma today announced a joint venture, Bone-Tech, to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. Bone-Tech brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of osteoarthritis with Emultech’s world-leading microfluidics’ microspheres